Scandinavian ChemoTech’s Clinical Development and Medical Affairs Newsletter for Tumour Specific Electroporation™ - TSE
ChemoTech's Chief Medical Officer, Suhail Mufti, provides an update on the clinical development and strategy of Medical Affairs.The purpose of this newsletter is to provide investors and the public with regular updates and insights into the progress, achievements, and advancements of our TSE technology. We aim to foster transparency and share key milestones, patient success stories, and important clinical trial updates in the further development of TSE.
Our goal is to keep our stakeholders informed and engaged in our mission to advance oncology treatment options with this innovative